Home › merck
 

Keywords :   


Tag: merck

Christina Applegate and Merck Urge Insomnia Sufferers to Learn Why Theyre So Awake

2016-04-28 14:00:23| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. Christina Applegate Shares Personal Struggle with Insomnia and Encourages Others to Educate Themselves about the Wake and Sleep Systems in the Brain KENILWORTH, N.J. Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it is teaming up with Emmy Award-winning actress Christina Applegate to educate the millions of Americans struggling with insomnia. An insomnia sufferer for much of her adult life, Applegate is sharing her personal experience to inspire others to learn more about how to get the sleep they need. Language: English read more

Tags: learn why christina urge

 

Merck Animal Health to Acquire Worldwide Rights to Whisper Veterinary Stethoscope System

2016-04-19 23:00:00| Merck.com - Corporate News

Dateline City: MADISON, N.J. Non-Invasive Device Helps Diagnose Bovine Respiratory Disease MADISON, N.J.--(BUSINESS WIRE)--Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced plans to acquire worldwide rights for the Whisper Veterinary Stethoscope System from Minnesota-based Geissler Companies. The Whisper Veterinary Stethoscope System is a Bovine Respiratory Disease (BRD) detection system which is used to determine the severity of an animals lung condition so that the appropriate treatment regimen can be started to protect the health of the animal. Language: English Contact: Merck Animal HealthAmy Firsching, 973-937-5453 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: rights system health worldwide

 
 

Merck Statement on Blueprint Project Findings Presented at the American Association for Cancer Research 2016 Annual Meeting

2016-04-19 20:05:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, is proud to be a part of the Blueprint PD-L1 Assay Comparison Project, an important initiative to compare several new diagnostic tests for the immune biomarker PD-L1 in non-small cell lung cancer (NSCLC). Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558An Phan, 908-255-6325orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: research american project statement

 

Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA (pembrolizumab) in Classical Hodgkin Lymphoma (cHL)

2016-04-18 14:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. Fourth Designation for KEYTRUDA Follows Breakthrough Status in Advanced Melanoma, Non-Small Cell Lung Cancer, and Colorectal Cancer KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma (cHL). This is the fourth Breakthrough Therapy Designation granted for KEYTRUDA. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558An Phan, 908-255-6325orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: food administration classical drug

 

Merck Announces Results From Phase 3 Studies of ZEPATIER (Elbasvir and Grazoprevir) in Chronic Hepatitis C Patient Populations at The International Liver Congress

2016-04-16 07:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from two Phase 3 clinical trials evaluating ZEPATIER (elbasvir and grazoprevir) 50mg/100mg tablets in chronic hepatitis C (HCV) patients with inherited blood disorders (C-EDGE IBLD) and in patients with a history of intravenous drug use who are receiving opioid agonist therapy (C-EDGE CO-STAR), respectively. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Sarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: the results international studies

 

Sites : [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] next »